Signaturefd LLC Increases Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Signaturefd LLC increased its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 43.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 65,097 shares of the company’s stock after acquiring an additional 19,786 shares during the period. Signaturefd LLC’s holdings in Takeda Pharmaceutical were worth $862,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC raised its holdings in Takeda Pharmaceutical by 10.9% in the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after purchasing an additional 286,052 shares in the last quarter. Stifel Financial Corp raised its holdings in Takeda Pharmaceutical by 103.9% in the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after purchasing an additional 224,594 shares in the last quarter. Crossmark Global Holdings Inc. raised its holdings in Takeda Pharmaceutical by 284.9% in the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock worth $2,787,000 after purchasing an additional 155,795 shares in the last quarter. Raymond James Financial Inc. bought a new position in Takeda Pharmaceutical in the fourth quarter worth $1,447,000. Finally, Verition Fund Management LLC bought a new position in Takeda Pharmaceutical in the third quarter worth $1,533,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

TAK opened at $15.14 on Thursday. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.24. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a fifty day simple moving average of $13.87 and a two-hundred day simple moving average of $13.91. The company has a market cap of $48.16 billion, a price-to-earnings ratio of 37.84, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.